Cited by 317Peroxisome Proliferator-Activated ReceptorsCholesterol and Lipid MetabolismParaoxonase enzyme and polymorphisms

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Activation of PPARδ alters lipid metabolism in db/db mice

Open access

Leibowitz, Mark D., Fiévet, Catherine, Hennuyer, Nathalie, Peinado-Onsurbe, Julia, Duez, Hélène, Berger, Joel, Cullinan, Catherine A., Sparrow, Carl P., Baffic, Joanne, Berger, Gregory D., Santini, Conrad, Marquis, Robert W., Tolman, Richard L., Smith, Roy G., Moller, David E., Auwerx, Johan·2000·FEBS Letters

DOI 10.1016/s0014-5793(00)01554-4

Open this paper in CoChat — free account Open PDF

Abstract

Peroxisome proliferator‐activated receptors (PPARs) are nuclear receptors, which heterodimerize with the retinoid X receptor and bind to peroxisome proliferator response elements in the promoters of regulated genes. Despite the wealth of information available on the function of PPARα and PPARγ, relatively little is known about the most widely expressed PPAR subtype, PPARδ. Here we show that treatment of insulin resistant db/db mice with the PPARδ agonist L‐165 041, at doses that had no effect on either glucose or triglycerides, raised total plasma cholesterol concentrations. The increased cholesterol was primarily associated with high density lipoprotein (HDL) particles, as shown by fast protein liquid chromatography analysis. These data were corroborated by the chemical analysis of the lipoproteins isolated by ultracentrifugation, demonstrating that treatment with L‐165 041 produced an increase in circulating HDL without major changes in very low or low density lipoproteins. White adipose tissue lipoprotein lipase activity was reduced following treatment with the PPARδ ligand, but was increased by a PPARγ agonist. These data suggest both that PPARδ is involved in the regulation of cholesterol metabolism in db/db mice and that PPARδ ligands could potentially have therapeutic value.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s0014-5793(00)01554-4

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ)
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,645
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
FORMAN, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,857
Differential expression and activation of a family of murine peroxisome proliferator-activated receptors.
Kliewer, S. A., FORMAN, B. M., Blumberg, B., Ong, E. S., Borgmeyer, U., Mangelsdorf, D. J., Umesono, K., & Evans, R. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.15.7355 · Cited by 1,402
Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors
Dreyer, C., Krey, G. D., Keller, H., Givel, F., Helftenbein, G., & Wahli, W. (1992) · Cell · doi:10.1016/0092-8674(92)90031-7 · Cited by 1,393
Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression
Schoonjans, K., Staels, B., & Auwerx, J. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42003-6 · Cited by 1,216
Self-citation
PPARalpha and PPARgamma activators direct a distinct tissue‐specific transcriptional response via a PPRE in the lipoprotein lipase gene.
Schoonjans, K., Peinado‐Onsurbe, J., Lefebvre, A. M., Heyman, R. A., Briggs, M., Deeb, S., Staels, B., & Auwerx, J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00918.x · Cited by 1,173
Self-citation
PPARδ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs
He, T., Chan, T. A.-T., Vogelstein, B., & Kinzler, K. W. (1999) · Cell · doi:10.1016/s0092-8674(00)81664-5 · Cited by 1,083
Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes
Saltiel, A. R., & Olefsky, J. M. (1996) · Diabetes · doi:10.2337/diab.45.12.1661 · Cited by 1,050

Show all 26 references

Research works printed but not linked: 2

10.1210/en.137.10.4189 · DOI · Paper page
10.1210/me.6.10.1634 · DOI

Sorted by citations

Items 101–200 of 317

Peroxisome proliferator activated receptor delta genotype in relation to cardiovascular risk factors and risk of coronary heart disease in hypercholesterolaemic men
Skogsberg, J., McMahon, A. D., Karpe, F., Hamsten, A., Packard, C. J., Ehrenborg, E., & Study, O. B. O. T. W. O. S. C. P. (2003) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2003.01236.x · Cited by 84
PPAR agonists in the treatment of atherosclerosis
Francis, G. A. (2003) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(03)00014-6 · Cited by 81
Resveratrol ameliorates endothelial dysfunction in diabetic and obese mice through sirtuin 1 and peroxisome proliferator-activated receptor δ
Cheang, W. S., Wong, W. T., Wang, L., Cheng, C. K., Lau, C. W., Ronald, C. W., Xu, A., Wang, N., Huang, Y., & Tian, X. Y. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.041 · Cited by 80
Peroxisome Proliferator‐Activated Receptor β/δ in the Brain: Facts and Hypothesis
Hall, M. G., Quignodon, L., & Desvergne, B. (2008) · PPAR Research · doi:10.1155/2008/780452 · Cited by 80
Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia
Choi, Y., Roberts, B. K., Wang, X., Geaney, J. C., Naim, S., Wojnoonski, K., Karpf, D. B., & Krauss, R. M. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.10.029 · Cited by 78
Activation of PPAR-δ in isolated rat skeletal muscle switches fuel preference from glucose to fatty acids
Brunmair, B., Staniek, K., Dörig, J., Szöcs, Z., Stadlbauer, K., Marian, V., Gras, F., Anderwald, C. H., Nohl, H., Waldhäusl, W. K., et al. (2006) · Diabetologia · doi:10.1007/s00125-006-0357-6 · Cited by 79
The Regulation of Uncoupling Protein-2 Gene Expression by ω-6 Polyunsaturated Fatty Acids in Human Skeletal Muscle Cells Involves Multiple Pathways, Including the Nuclear Receptor Peroxisome Proliferator-activated Receptor β
Chevillotte, E., Rieusset, J., Roques, M., Desage, M., & Vidal, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008010200 · Cited by 77
PPARs and LXRs: atherosclerosis goes nuclear
Barish, G. D., & Evans, R. M. (2004) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2004.03.003 · Cited by 76
The Effect of PPAR α , PPAR δ , PPAR γ , and PPARpan Agonists on Body Weight, Body Mass, and Serum Lipid Profiles in Diet-Induced Obese AKR/J Mice
Harrington, W. W., Britt, C. S., Wilson, J. G., Milliken, N. O., Binz, J. G., Lobe, D. C., Oliver, W. R., Lewis, M. C., & Ignar, D. M. (2007) · PPAR Research · doi:10.1155/2007/97125 · Cited by 74
Transcriptional control of physiological and pathological processes by the nuclear receptor PPARβ/δ
Tan, N. S., Vázquez‐Carrera, M., Montagner, A., Sng, M. K., Guillou, H., & Wahli, W. (2016) · Progress in Lipid Research · doi:10.1016/j.plipres.2016.09.001 · Cited by 75
Role of PPARγ in macrophage biology and atherosclerosis
Zhang, L., & Chawla, A. (2004) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2004.10.006 · Cited by 74
Pharmacological activation of PPARβ promotes rapid and calcineurin-dependent fiber remodeling and angiogenesis in mouse skeletal muscle
Gaudel, C., Schwartz, C., Giordano, C., Abumrad, N. A., & Grimaldi, P. A. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00581.2007 · Cited by 76
Quantitative Trait Loci and Candidate Genes Regulating HDL Cholesterol
Wang, X., & Paigen, B. J. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000030201.29121.a3 · Cited by 73
Nuclear Receptors and Inflammatory Diseases
Wang, K., & Wan, Y. Y. (2008) · Experimental Biology and Medicine · doi:10.3181/0708-mr-231 · Cited by 72
Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines
Girroir, E. E., Hollingshead, H. E., Billin, A. N., Willson, T. M., Robertson, G. P., Sharma, A. K., Amin, S., Gonzalez, F. J., & Peters, J. M. (2007) · Toxicology · doi:10.1016/j.tox.2007.10.023 · Cited by 72
Nuclear receptors as drug targets in metabolic diseases: new approaches to therapy
Tobin, J. F., & Freedman, L. P. (2006) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2006.07.004 · Cited by 72
Peroxisome proliferator-activated receptor δ (PPARδ), a novel target site for drug discovery in metabolic syndrome
Takahashi, S., Tanaka, T., Kodama, T., & Sakai, J. (2006) · Pharmacological Research · doi:10.1016/j.phrs.2006.03.019 · Cited by 71
Biological Characterization of a Heterodimer-Selective Retinoid X Receptor Modulator: Potential Benefits for the Treatment of Type 2 Diabetes
Leibowitz, M. D., Ardecky, R., Boehm, M. F., Broderick, C. L., Carfagna, M. A., Crombie, D. L., D’Arrigo, J., Etgen, G. J., Faul, M. M., Grese, T. A., et al. (2005) · Endocrinology · doi:10.1210/en.2005-0690 · Cited by 71
Self-citation
Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) ligands do not potentiate growth of human cancer cell lines
Hollingshead, H. E., Killins, R. L., Borland, M. G., Girroir, E. E., Billin, A. N., Willson, T. M., Sharma, A. K., Amin, S., Gonzalez, F. J., & Peters, J. M. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm183 · Cited by 71
Ligand‐dependent contribution of RXRβ to cholesterol homeostasis in Sertoli cells
Mascrez, B., Ghyselinck, N. B., 渡辺, 光., Annicotte, J., Chambon, P., Auwerx, J. H., & Mark, M. P. (2004) · EMBO Reports · doi:10.1038/sj.embor.7400094 · Cited by 70
Self-citation
Peroxisome proliferator-activated receptor β stimulation induces rapid cardiac growth and angiogenesis via direct activation of calcineurin
Wagner, N., Jehl-Piétri, C., Lopez, P., Murdaca, J., Giordano, C., Schwartz, C., Gounon, P., Hatem, S. N., Grimaldi, P. A., & Wagner, K. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp106 · Cited by 70
Peroxisome proliferator‐activated receptor (PPAR) modulators: Diabetes and beyond*
Jones, A. B. (2001) · Medicinal Research Reviews · doi:10.1002/med.1025 · Cited by 67
PPARδ Activation Protects Endothelial Function in Diabetic Mice
Tian, X. Y., Wong, W. T., Wang, N., Lu, Y., Cheang, W. S., Liu, J., Liu, L., Liu, Y., Lee, S. S. T., Chen, Z., et al. (2012) · Diabetes · doi:10.2337/db12-0117 · Cited by 67
Both the Peroxisome Proliferator‐Activated Receptor δ Agonist, GW0742, and Ezetimibe Promote Reverse Cholesterol Transport in Mice by Reducing Intestinal Reabsorption of HDL‐Derived Cholesterol
Briand, F., Naik, S. U., Fuki, I. V., Millar, J. S., Macphee, C. H., Walker, M., Billheimer, J. T., Rothblat, G. H., & Rader, D. J. (2009) · Clinical and Translational Science · doi:10.1111/j.1752-8062.2009.00098.x · Cited by 66
Peroxisome proliferator-activated receptors and angiogenesis
Biscetti, F., Straface, G., Pitocco, D., Zaccardi, F., Ghirlanda, G., & Flex, A. (2009) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.04.011 · Cited by 65
Reverse cholesterol transport, high density lipoproteins and HDL cholesterol: recent data
Fredenrich, A., & Bayer, P. M. (2003) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70029-0 · Cited by 65
A Short and Efficient Synthesis of the Pharmacological Research Tool GW501516 for the Peroxisome Proliferator-Activated Receptor δ
Wei, Z.-L., & Kozikowski, A. P. (2003) · The Journal of Organic Chemistry · doi:10.1021/jo035140g · Cited by 64
Lipid‐sensing nuclear receptors in the pathophysiology and treatment of the metabolic syndrome
Vacca, M., Degirolamo, C., Mariani‐Costantini, R., Palasciano, G., & Moschetta, A. (2011) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.137 · Cited by 66
Fatty Acid and Glucose Sensors in Hepatic Lipid Metabolism: Implications in NAFLD
Allison, M., Griffin, J. L., Vacca, M., & Vidal‐Puig, A. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1562945 · Cited by 67
Dissecting the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in colon, breast, and lung carcinogenesis
Peters, J. M., Foreman, J. E., & Gonzalez, F. J. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9320-1 · Cited by 64
Ligand-activated PPARβ efficiently represses the induction of LXR-dependent promoter activity through competition with RXR
Matsusue, K., Miyoshi, A., Yamano, S., & Gonzalez, F. J. (2006) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2006.05.005 · Cited by 60
Highlights on U.S. FDA-approved halogen-containing drugs in 2024
Ali, S., Tian, X., Meccia, S. A., & Zhou, J. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117380 · Cited by 63
PPARγ pathway activation results in apoptosis and COX-2 inhibition in HepG2 cells
Li, M. (2003) · World Journal of Gastroenterology · doi:10.3748/wjg.v9.i6.1220 · Cited by 59
Effect of Topical PPARβ/δ and PPARγ Agonists on Plaque Psoriasis
Kuenzli, S., & Saurat, J. ‐. (2003) · Dermatology · doi:10.1159/000068897 · Cited by 60
Prostaglandins and fatty acids regulate transcriptional signaling via the peroxisome proliferator activated receptor nuclear receptors
Dussault, I., & FORMAN, B. M. (2000) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(00)00071-x · Cited by 58
PPAR-β/δ agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home
Billin, A. N. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.10.1465 · Cited by 58
Peroxisome proliferator-activated receptor-δ, a regulator of oxidative capacity, fuel switching and cholesterol transport
Fürnsinn, C., Willson, T. M., & Brunmair, B. (2006) · Diabetologia · doi:10.1007/s00125-006-0492-0 · Cited by 56
Single Nucleotide Polymorphisms in the Peroxisome Proliferator–Activated Receptor δ Gene Are Associated With Skeletal Muscle Glucose Uptake
Vänttinen, M., Nuutila, P., Kuulasmaa, T., Pihlajamäki, J., Hällsten, K., Virtanen, K. A., Läutamaki, R., Peltoniemi, P., Takala, T., Viljanen, A. P. M., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3587 · Cited by 57
Peroxisome proliferator-activated receptor-δ polymorphisms are associated with physical performance and plasma lipids: the HERITAGE Family Study
Hautala, A. J., Leon, A. S., Skinner, J. S., Rao, D. C., Bouchard, C., & Rankinen, T. (2007) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01092.2006 · Cited by 55
Novel Approach to Treat Insulin Resistance, Type 2 Diabetes, and the Metabolic Syndrome: Simultaneous Activation of PPARα, PPARγ, and PPARδ
Evans, J. L., Lin, J., & Goldfine, I. D. (2005) · Current Diabetes Reviews · doi:10.2174/157339905774574365 · Cited by 56
Regulatory functions of PPARβ in metabolism: implications for the treatment of metabolic syndrome
Grimaldi, P. A. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.02.006 · Cited by 56
Features of the metabolic syndrome are modulated by an interaction between the peroxisome proliferator-activated receptor-delta −87T>C polymorphism and dietary fat in French-Canadians
Robitaille, J., Gaudet, D., Përusse, L., & Vohl, M. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803450 · Cited by 53
Crosstalk between PPARs and gut microbiota in NAFLD
Wu, L., Li, J., Feng, J., Ji, J., Yu, Q., Li, Y., Zheng, Y., Dai, W., Wu, J., & Guo, C. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111255 · Cited by 52
Association of peroxisome proliferator-activated receptor delta +294T/C with body mass index and interaction with peroxisome proliferator-activated receptor alpha L162V
Aberle, J., Hopfer, I., Beil, F., & Seedorf, U. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803345 · Cited by 50
The Role of PPARs in Breast Cancer
Zhao, B., Xin, Z., Ren, P., & Wu, H. (2022) · Cells · doi:10.3390/cells12010130 · Cited by 53
Interferon Regulatory Factor Signalings in Cardiometabolic Diseases
Zhang, X., Zhang, P., & Li, H. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.04898 · Cited by 51
Peroxisome Proliferator-Activated Receptors and the Cardiovascular System
Chen, Y. E., Fu, M., Zhang, J., Zhu, X., Lin, Y., Akinbami, M. A., & Song, Q. (2003) · Vitamins and hormones · doi:10.1016/s0083-6729(03)01005-7 · Cited by 50
Genomic organization of the mouse peroxisome proliferator-activated receptor β/δ gene: alternative promoter usage and splicing yield transcripts exhibiting differential translational efficiency
Larsen, L. K., Amri, E., Mandrup, S., Pacot, C., & Kristiansen, K. (2002) · Biochemical Journal · doi:10.1042/bj20011821 · Cited by 50
Peroxisome proliferator-activated receptors β/δ: emerging roles for a previously neglected third family member
Michalik, L., Desvergne, B., & Wahli, W. (2003) · Current Opinion in Lipidology · doi:10.1097/00041433-200304000-00003 · Cited by 49
Association of the T+294C polymorphism in PPAR δ with low HDL cholesterol and coronary heart disease risk in women
Aberle, J., Hopfer, I., Beil, F. U., & Seedorf, U. (2006) · International Journal of Medical Sciences · doi:10.7150/ijms.3.108 · Cited by 49
Novel Bisaryl Substituted Thiazoles and Oxazoles as Highly Potent and Selective Peroxisome Proliferator-Activated Receptor δ Agonists
Epple, R., Cow, C., Yongping, X., Azimioara, M. D., Russo, R., Wang, X., Wityak, J., Karanewsky, D. S., Tuntland, T., Nguyen-Tran, V. T. B., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9007399 · Cited by 48
Common Pathological Processes and Transcriptional Pathways in Alzheimer's Disease and Type 2 Diabetes
Jones, A., Kulozik, P., Ostertag, A., & Herzig, S. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0973 · Cited by 47
New Therapeutic Target for Metabolic Syndrome: PPAR.DELTA.
Takahashi, S., Tanaka, T., & Sakai, J. (2007) · Endocrine Journal · doi:10.1507/endocrj.kr-99 · Cited by 46
Peroxisome proliferator-activated receptor-? as a target for wound healing drugs
Tan, N. S., Michalik, L., Desvergne, B., & Wahli, W. (2004) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.8.1.39 · Cited by 46
Intestinal PPARδ protects against diet-induced obesity, insulin resistance and dyslipidemia
Doktorova, M., Zwarts, I., van Zutphen, T., van Dijk, T. H., Bloks, V. W., Harkema, L., de Bruin, A., Downes, M., Evans, R. M., Verkade, H. J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-00889-z · Cited by 47
Peroxisome Proliferator-Activated Receptor Isoform Expression Changes in Human Gestational Tissues with Labor at Term
Berry, E. B. E., Eykholt, R. L., Helliwell, R. J. A., Gilmour, R. S., Mitchell, M. D., & Marvin, K. W. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.6.1586 · Cited by 44
Variation in the peroxisome proliferator-activated receptor δ gene in relation to common metabolic traits in 7,495 middle-aged white people
Grarup, N., Albrechtsen, A., Ek, J., Borch‐Johnsen, K., Jørgensen, T., Schmitz, O., Hansen, T. F., & Pedersen, O. B. (2007) · Diabetologia · doi:10.1007/s00125-007-0668-2 · Cited by 43
Functional characterization of peroxisome proliferator‐activated receptor‐β/δ expression in colon cancer
Foreman, J. E., Chang, W., Palkar, P. S., Zhu, B., Borland, M. G., Williams, J. L., Kramer, L. R., Clapper, M. L., Gonzalez, F. J., & Peters, J. M. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20757 · Cited by 43
Drug Insight: thiazolidinediones and diabetic nephropathy—relevance to renoprotection
Panchapakesan, U., Chen, X., & Pollock, C. A. (2005) · Nature Reviews Nephrology · doi:10.1038/ncpneph0029 · Cited by 43
Effect of the peroxisome proliferator‐activated receptor β activator GW0742 in rat cultured cerebellar granule neurons
Smith, S. A., Monteith, G. R., Robinson, J. A., Venkata, N. G., May, F. J., & Roberts‐Thomson, S. J. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20153 · Cited by 43
Predominance of a Proinflammatory Phenotype in Monocyte-Derived Macrophages From Subjects With Low Plasma HDL-Cholesterol
Sarov‐Blat, L., Kiss, R. S., Haidar, B., Kavaslar, N., Jaye, M., Bertiaux, M., Steplewski, K. M., Hurle, M. R., Sprecher, D. L., McPherson, R., et al. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.106.138990 · Cited by 44
Fatty acid regulation of gene expression
Grimaldi, P. A. (2001) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/00075197-200109000-00015 · Cited by 46
Emerging roles of PPARδ in metabolism
Seedorf, U., & Aberle, J. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.04.017 · Cited by 41
Novel peroxisome proliferator-activated receptor ligands for Type 2 diabetes and the metabolic syndrome
Miller, A. R., & Etgen, G. J. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.9.1489 · Cited by 41
Triacylglycerol-rich lipoprotein margination: a potential surrogate for whole-body lipoprotein lipase activity and effects of eicosapentaenoic and docosahexaenoic acids
Park, Y., Jones, P. G., & Harris, W. S. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/80.1.45 · Cited by 41
Peroxisome Proliferator‐Activated Receptor Ligands and Their Role in Chronic Myeloid Leukemia: Therapeutic Strategies
Yousefi, B., Samadi, N., Baradaran, B., Shafiei‐Irannejad, V., & Zarghami, N. (2016) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12737 · Cited by 41
Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes, and Cardiovascular Disease
Gilde, A. J., Fruchart, J., & Staels, B. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.04.097 · Cited by 42
Ligand and coactivator recruitment preferences of peroxisome proliferator activated receptor α
Mukherjee, R., Sun, S., Santomenna, L. D., Miao, B., Walton, H. L., Liao, B., Locke, K. T., Zhang, J.-H., Nguyen, S. H., Zhang, L. T., et al. (2002) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(02)00066-3 · Cited by 41
Ligand activation of peroxisome proliferator-activated receptor β/δ (PPARβ/δ) inhibits chemically induced skin tumorigenesis
Bility, M. T., Devlin-Durante, M. K., Blazanin, N., Glick, A. B., Ward, J. M., Kang, B. H., Kennett, M. J., Gonzalez, F. J., & Peters, J. M. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn219 · Cited by 42
Diallyl disulfide potentiates anti-obesity effect of green tea in high-fat/high-sucrose diet-induced obesity
Bae, J., Kumazoe, M., Fujimura, Y., & Tachibana, H. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.10.014 · Cited by 42
Investigational PPAR-γ agonists for the treatment of Type 2 diabetes
Savkur, R. S., & Miller, A. R. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.7.763 · Cited by 40
PPAR‐δ in Vascular Pathophysiology
Wang, N. (2008) · PPAR Research · doi:10.1155/2008/164163 · Cited by 39
Roles of Skeletal Muscle and Peroxisome Proliferator-Activated Receptors in the Development and Treatment of Obesity
López‐Soriano, J., Chiellini, C., Maffei, M., Grimaldi, P. A., & Argilés, J. M. A. (2006) · Endocrine Reviews · doi:10.1210/er.2005-0012 · Cited by 40
Peroxisome proliferator-activated receptor β/δ as a therapeutic target for metabolic diseases
Bedu, E., Wahli, W., & Desvergne, B. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.4.861 · Cited by 40
1,3,5-Trisubstituted aryls as highly selective PPARδ agonists
Epple, R., Azimioara, M. D., Russo, R., Bursulaya, B. D., Tian, S., Gerken, A., & Iskandar, M. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.02.079 · Cited by 39
Therapeutic modulation of transcription factor activity
Emery, J. G., Ohlstein, E. H., & Jaye, M. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01661-8 · Cited by 39
Nutrigenomics and its Impact on Life Style Associated Metabolic Diseases
Rana, S., Kumar, S., Rathore, N., Padwad, Y. S., & Bhushan, S. (2016) · Current Genomics · doi:10.2174/1389202917666160202220422 · Cited by 40
Targeting the peroxisome proliferator-activated receptors (PPARs) in spinal cord injury
Esposito, E., & Cuzzocrea, S. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.581231 · Cited by 38
Regulation of peroxisome proliferator‐activated receptor‐β/δ by the APC/β‐CATENIN pathway and nonsteroidal antiinflammatory drugs
Foreman, J. E., Sorg, J. M., McGinnis, K. S., Rigas, B., Williams, J. L., Clapper, M. L., Gonzalez, F. J., & Peters, J. M. (2009) · Molecular Carcinogenesis · doi:10.1002/mc.20546 · Cited by 37
Orphan nuclear receptors: therapeutic opportunities in skeletal muscle
Smith, A. G., & Muscat, G. E. O. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00476.2005 · Cited by 37
Activation of Peroxisome Proliferator-Activated Receptor–δ Enhances Regenerative Capacity of Human Endothelial Progenitor Cells by Stimulating Biosynthesis of Tetrahydrobiopterin
He, T., Smith, L. A., Lü, T., Joyner, M. J., & Katušić, Z. S. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.172189 · Cited by 36
Peroxisome proliferator-activated receptor delta and cardiovascular disease
Ehrenborg, E., & Skogsberg, J. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.08.027 · Cited by 36
Peroxisome Proliferator-activated Receptors in Atherosclerosis and Inflammation—An Update
Elangbam, C. S., Tyler, R. D., & Lightfoot, R. M. (2001) · Toxicologic Pathology · doi:10.1080/019262301317052495 · Cited by 35
Chronic peroxisome proliferator-activated receptorβ/δ agonist GW0742 prevents hypertension, vascular inflammatory and oxidative status, and endothelial dysfunction in diet-induced obesity
Toral, M., Gómez‐Guzmán, M., Jiménez, R., Romero, M., Zarzuelo-Romero, M. J., Utrilla, M. P., Hermenegildo, C., Cogolludo, A. L., Pérez‐Vizcaíno, F., Gálvez, J., et al. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000634 · Cited by 35
Retinoic acid activation of peroxisome proliferation-activated receptor δ represses obesity and insulin resistance
Wolf, G. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.2009.00261.x · Cited by 35
Peroxisome Proliferator-Activated Receptor (PPAR)-?? as a Target for Wound Healing Drugs
Tan, N. S., Michalik, L., Desvergne, B., & Wahli, W. (2003) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200304080-00001 · Cited by 35
PPAR β activation restores the high glucose‐induced impairment of insulin signalling in endothelial cells
Quintela, A. M., Jiménez, R., Piqueras, L., Gómez‐Guzmán, M., Haro, J., Zarzuelo-Romero, M. J., Cogolludo, A. L., Sanz, M., Toral, M., Romero, M., et al. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12646 · Cited by 34
Cryptochrome and Period Proteins Are Regulated by the CLOCK/BMAL1 Gene: Crosstalk between the PPARs/RXRα‐Regulated and CLOCK/BMAL1‐Regulated Systems
Nakamura, K.-I., Inoue, I., Takahashi, S., Komoda, T., & Katayama, S. (2008) · PPAR Research · doi:10.1155/2008/348610 · Cited by 33
A Novel Selective Peroxisome Proliferator-Activated Receptor α Agonist, 2-Methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), Potently Decreases Plasma Triglyceride and Glucose Levels and Modifies Lipoprotein Profiles in KK-Ay Mice
Kuwabara, K., Murakami, K., Todo, M., Aoki, T., Asaki, T., Murai, M., & Yano, J. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.064659 · Cited by 34
Regulation of LXR by fatty acids, insulin, growth hormone and tumor necrosis factor-α in rainbow trout myocytes
Cruz-Garcia, L., Sánchez-Gurmaches, J., Gutiérrez, J., & Navarro, I. (2011) · Comparative Biochemistry and Physiology Part A Molecular & Integrative Physiology · doi:10.1016/j.cbpa.2011.05.013 · Cited by 32
The Role of Peroxisome Proliferator-Activated Receptor β/δ on the Inflammatory Basis of Metabolic Disease
Coll, T., Barroso, E., Álvarez-Guardia, D., Serrano, L., Salvadó, L., Merlos, M., Palomer, X., & Vázquez‐Carrera, M. (2010) · PPAR Research · doi:10.1155/2010/368467 · Cited by 33
PPARδ activation in human myotubes increases mitochondrial fatty acid oxidative capacity and reduces glucose utilization by a switch in substrate preference
Feng, Y. Z., Nikolić, N., Bakke, S. S., Boekschoten, M. V., Kersten, S., Kase, E. T., Rustan, A. C., & Thoresen, G. H. (2013) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2013.829105 · Cited by 35
Up-regulation of PPARγ coactivator-1α as a strategy for preventing and reversing insulin resistance and obesity
McCarty, M. F. (2004) · Medical Hypotheses · doi:10.1016/j.mehy.2004.03.034 · Cited by 32
Peroxisome Proliferator-activated Receptor β/δ Induces Myogenesis by Modulating Myostatin Activity
Bonala, S., Lokireddy, S., Harikumar, A., Teng, S., Wahli, W., Sharma, M., McFarlane, C., & Kambadur, R. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.319145 · Cited by 33
Retracted
The peroxisome proliferator-activated receptor delta +294T/C polymorphism in relation to lipoprotein metabolism in patients with diabetes mellitus type 2 and in non-diabetic controls
Gouni-Berthold, I., Giannakidou, E., Faust, M., Berthold, H. K., & Krone, W. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.03.016 · Cited by 31
Impact of feeding polyunsaturated fatty acids on cholesterol metabolism of dyslipidemic obese rats of WNIN/GR-Ob strain
Alex, S., Jeyakumar, S. M., Jayashree, T., Giridharan, N. V., & Vajreswari, A. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.08.021 · Cited by 29
Structural design and synthesis of arylalkynyl amide-type peroxisome proliferator-activated receptor γ (PPARγ)-selective antagonists based on the helix12-folding inhibition hypothesis
Ōhashi, M., Gamo, K., Tanaka, Y., Waki, M., Beniyama, Y., Matsuno, K., Wada, J., Tenta, M., Eguchi, J., Makishima, M., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.11.017 · Cited by 30
Identification, organ expression and ligand-dependent expression levels of peroxisome proliferator activated receptors in grass carp (Ctenopharyngodon idella)
He, S., Liang, X., Qu, C., Huang, W. Z., Shen, D., Zhang, W., & Mai, K. (2011) · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology · doi:10.1016/j.cbpc.2011.10.008 · Cited by 29
Peroxisome proliferator-activated receptor β activation promotes myonuclear accretion in skeletal muscle of adult and aged mice
Giordano, C., Rousseau, A., Wagner, N., Gaudel, C., Murdaca, J., Jehl-Piétri, C., Sibille, B., Grimaldi, P. A., & Lopez, P. (2009) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-009-0676-9 · Cited by 33
Peroxisome proliferator-activated receptor β expression in human breast epithelial cell lines of tumorigenic and non-tumorigenic origin
Suchanek, K. M., May, F. J., Lee, W. J., Holman, N. A., & Roberts‐Thomson, S. J. (2002) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(02)00025-0 · Cited by 29

Authors: Leibowitz, M. D., Fiévet, C., Hennuyer, N., Peinado-Onsurbe, J., Duez, H., Berger, J., Cullinan, C. A., Sparrow, C. P., Baffic, J., Berger, G. D., Santini, C., Marquis, R. W., Tolman, R. L., Smith, R. G., Moller, D. E., & Auwerx, J.
Affiliations: Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Inserm (FR)
Corresponding author: Leibowitz, Mark D.
ORCID: Hennuyer, Nathalie
Duez, Hélène
Santini, Conrad
Moller, David E.
Auwerx, Johan
Venue: FEBS Letters
Publisher: Wiley
Published: 2000-05-12
Volume: 473
Issue: 3
Pages: 333-336
ISSN: 0014-5793 (ISSN-L)
1873-3468
DOI: 10.1016/s0014-5793(00)01554-4
OpenAlex: W2024254257
Cited by: 308
References: 26
Citations by year: 2025: 2 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 3 · 2019: 2 · 2018: 9 · 2017: 4 · 2016: 6 · 2015: 9 · 2014: 7 · 2013: 13 · 2012: 8
FWCI: 7.23
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: FEBS Letters (publishedVersion)
PubMed (publishedVersion)
HAL (submittedVersion)
Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
Keywords: PPARδ, db/db mice, type 2 diabetes, insulin resistance, HDL cholesterol, serum cholesterol, lipoprotein lipase, white adipose tissue, PPARγ agonists, lipid metabolism, nuclear receptors
MeSH terms: Acetates, Adipose Tissue, Animals, Blood Glucose, Cholesterol, Chromatography, Liquid, DNA-Binding Proteins, Ligands, Lipids, Lipoprotein Lipase, Lipoproteins, Male, Mice, Inbred C57BL, Mice, Mutant Strains, Phenols, Phenoxyacetates, Transcription Factors, Triglycerides, Ultracentrifugation, Receptors, Cytoplasmic and Nuclear, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Activation of PPARδ alters lipid metabolism in db/db mice

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks